Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUSNASDAQ:BLTENASDAQ:HRMYNASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsBLTEBelite Bio$64.07-2.4%$61.02$43.70▼$86.53$2.04B-1.4848,978 shs884 shsHRMYHarmony Biosciences$34.09+0.1%$31.51$26.47▼$41.61$1.96B0.82604,272 shs68,538 shsLGNDLigand Pharmaceuticals$101.02+0.1%$104.80$77.43▼$129.90$1.96B0.87116,212 shs36,619 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%BLTEBelite Bio+6.54%+1.56%+5.36%+14.76%+37.35%HRMYHarmony Biosciences+0.98%-0.23%+15.66%+0.59%+16.09%LGNDLigand Pharmaceuticals+0.72%-0.38%-9.40%-17.44%+18.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/ABLTEBelite Bio2.2213 of 5 stars3.53.00.00.02.10.80.6HRMYHarmony Biosciences4.9615 of 5 stars4.64.00.00.04.33.34.4LGNDLigand Pharmaceuticals4.7782 of 5 stars3.53.00.04.43.73.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUSAkouos 0.00N/AN/AN/ABLTEBelite Bio 3.00Buy$96.6750.88% UpsideHRMYHarmony Biosciences 3.11Buy$52.7854.82% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1444.67% UpsideCurrent Analyst Ratings BreakdownLatest AKUS, BLTE, LGND, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/8/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/26/2025BLTEBelite BioBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUSAkouosN/AN/AN/AN/A$4.90 per shareN/ABLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/AHRMYHarmony Biosciences$744.85M2.63$2.55 per share13.38$7.97 per share4.28LGNDLigand Pharmaceuticals$181.49M10.74$4.14 per share24.39$40.39 per share2.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/ABLTEBelite Bio-$31.63M-$1.36N/AN/AN/AN/A-31.94%-30.73%8/8/2025 (Estimated)HRMYHarmony Biosciences$128.85M$2.6216.1910.960.4717.98%23.16%14.24%8/5/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$7.1240.4727.23N/A29.68%4.95%4.39%8/5/2025 (Estimated)Latest AKUS, BLTE, LGND, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million3/17/2025Q4 2024BLTEBelite Bio-$0.30-$0.32-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUSAkouosN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUSAkouosN/A17.3017.30BLTEBelite BioN/A30.7330.73HRMYHarmony Biosciences0.283.243.20LGNDLigand PharmaceuticalsN/A12.4911.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUSAkouosN/ABLTEBelite Bio0.53%HRMYHarmony Biosciences86.23%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipAKUSAkouos4.80%BLTEBelite Bio13.29%HRMYHarmony Biosciences23.60%LGNDLigand Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableHRMYHarmony Biosciences20057.42 million39.47 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.78 millionOptionableAKUS, BLTE, LGND, and HRMY HeadlinesRecent News About These CompaniesBank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 25, 2025 | marketbeat.comCastleark Management LLC Cuts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 23, 2025 | marketbeat.comGraham Capital Management L.P. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 18, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by BrokeragesMay 18, 2025 | marketbeat.comDeutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 15, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.comMay 15, 2025 | marketbeat.comLigand to Ring the Nasdaq Opening Bell on May 19, 2025May 14, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Acquires $156,090.00 in StockMay 14, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Northern Trust CorpMay 13, 2025 | marketbeat.comLGND: 1Q:25 ResultsMay 12, 2025 | msn.comClark Capital Management Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 12, 2025 | marketbeat.comDriehaus Capital Management LLC Increases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 11, 2025 | marketbeat.comBaird Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 11, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings GuidanceMay 10, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...May 9, 2025 | finance.yahoo.comQ1 2025 Ligand Pharmaceuticals Inc Earnings Call TranscriptMay 9, 2025 | gurufocus.comLigand Pharmaceuticals Reports Strong Q1 2025 EarningsMay 8, 2025 | tipranks.comLigand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comLigand Pharmaceuticals Incorporated 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comLigand Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKUS, BLTE, LGND, and HRMY Company DescriptionsAkouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Belite Bio NASDAQ:BLTE$64.07 -1.57 (-2.39%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Harmony Biosciences NASDAQ:HRMY$34.09 +0.04 (+0.12%) As of 12:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Ligand Pharmaceuticals NASDAQ:LGND$101.02 +0.11 (+0.11%) As of 12:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
